Ars Pharmaceuticals Inc (SPRY)

$SPRY https://youtu.be/99ggXypKAaM

$SPRY 🤦🏻‍♂️

ARS PHARMACEUTICALS IS IN THE PROCESS OF RE PRICING UP UP & UP $ADMA $AXSM $MIRM $SPRY $TARS

$AQST I see… Some $SPRY investors spending more time attacking $AQST than supporting their own stock tells you everything. If you truly believe $AQST approval would bankrupt ARS Pharmaceuticals, then ask yourself one simple question: Why are you still holding? If your thesis depends on a competitor failing instead of your company winning, that is not investing. That is hoping. If you do not trust your position, selling and moving on makes more sense than complaining about another company. Meanwhile Aquestive Therapeutics keeps derisking, progressing, and attracting attention. Strong investments stand on their own fundamentals. Fear of competition usually means weakness. Just my view.

$AQST $SPRY did somebody say “allergists only “? I don’t think so…

$AQST $SPRY is hiring, there are 51 job openings available. When company has a good product, they sell it themselves and don’t rely on licensing and outsourcing. Does aqst have a chance?!

$SPRY is commercial stage @DividendVanguard Don’t fool yourself.

$SPRY why would they say they're in early stages of discussions for Fabry if a BO is imminent? That would definitely be interpreted as an intentional misleading statement to investors, which is illegal.

$SPRY is a clinical-stage biotech developing therapies for central nervous system disorders; its pipeline is early and represents a long-duration, high-risk investment.

$SPRY $NDAQ $RUT @Stocktwits Recent trading suggests short-term price movement is being driven more by off-exchange activity via dark pools, ATS desks, and broker internalization than by changes in fundamentals. When a large share of volume occurs away from lit markets, visible price discovery can lag, which appears to be happening here. Institutional and insider ownership exceeds 90%, leaving a highly constrained effective float. In this structure, relatively modest positioning flows-particularly short activity routed through dark pools/ATS desks/brokers - can delay and suppress price without reflecting genuine selling. There is little evidence of distribution by long-term institutions or retail investors. Borrow conditions have remained CHEAP for an extended period, but as Neffy’s competitive position strengthens and competing needle-free alternatives remain delayed 12+ months, the cost and risk of maintaining short borrow exposure should RISE materially. A failure of BORROW FEES to increase from here would be HIGHLY UNUSUAL given SPRY’s RECENT REGULATORY ACHIEVEMENTS, upcoming approvals and overall business trajectory. SPRY remains a float-constrained stock where price discovery appears suppressed and delayed, not broken. With growing sales momentum and multiple recent/upcoming regulatory milestones, A BORROW FEE SPIKE SHOULD BE INCOMING. In turn this should re price UP in the coming months!